drugset
drugset / Trial / NCT06643962

Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy

NCT06643962 ↗

Recruiting 83 enrolled Affiliated Hospital of Nantong University
NaSingle-groupOpen-labelTreatment

Summary

This single-center prospective cohort study aims to evaluate the efficacy and safety of Intensifying treatment with Venetoclax along with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) except acute promyelocytic leukemia (non-APL) and exhibiting lower early peripheral blast clearance rate (EPBCR) after standard Intensive Induction therapy (3+7 regimen).

Timeline

Start
2024-10-31
Primary completion
2025-12-31
Completion
2027-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule 400 mg Oral
Background Cytarabine Small molecule 100 mg/m2 Intravenous
Background Cytarabine Small molecule 1 g Intravenous
Background Cytarabine Small molecule 2 g Intravenous
Background Idarubicin Small molecule 6 mg/m2 Intravenous
Background Idarubicin Small molecule 10 mg/m2 Intravenous

Indications

acute myeloid leukemia